Apixmed: virtual assistant for personal health management enters the market
The Ukrainian startup Apixmed has developed a platform for personalized health management, utilizing genetic and medical data to provide individual recommendations. The team is currently seeking investments to scale in the European market.
Founded by Maryna Korshevniuk and Yevhenii Havryliuk, Apixmed brings together a powerful team of 10 specialists, including developers, medical experts, data analysts, and designers. The platform is positioned as a tool that helps users receive personalized action plans through uploaded medical and genetic data. This assists in making informed health decisions.
The startup aims to develop its algorithms based on over 20,000 data analyses and has already attracted funding exceeding €200,000. Notably, Apixmed has conducted successful pilots in Ukraine and is increasing its presence among clinic and laboratory clients.
International players like SelfDecode and DNAnexus stand out among market competitors, offering distinct solutions for B2C and B2B segments. However, unlike some competitors that have faced setbacks, such as 23andMe, Apixmed emphasizes integration with medical practice and providing personalized recommendations.
Personalized medicine is actively evolving, and the European market, which exceeds $70 billion, is growing annually by 10-12%. Apixmed plans to leverage this trend for business expansion, focusing on product localization and certification according to European standards.
| Indicator | Value |
|---|---|
| Secured funding | €200,000+ |
| Number of data sets processed | 20,000+ |
| Number of unique models | 500+ |
| Revenue growth | Tripled in 6 months |
